The addition of targeted immunotherapy will be safe and well tolerated and facilitate the
reduction of anthracycline exposure while preserving lymphoma disease control in
children, adolescents and young adults (CAYA) with mature B-cell non-Hodgkin lymphoma
(MB-NHL) and classical Hodgkin lymphoma (cHL).
Additional locations may be listed on ClinicalTrials.gov for NCT05253495.
Locations matching your search criteria
United States
Florida
Gainesville
UF Health Cancer Institute - GainesvilleStatus: Active
Name Not Available
The primary objective is 1) to determine feasibility and safety, as defined by dose
limiting toxicities (DLTs), of adding polatuzumab vedotin (Pv) in combination with
rituximab (RTX) containing French-American-British (FAB) chemoimmunotherapy, with reduced
dose anthracycline, in CAYA with intermediate and high risk newly diagnosed MB-NHL; 2) To
define the feasibility and safety, as defined by DLTs, of the addition of nivolumab to
the backbone of reduced toxicity chemoimmunotherapy with brentuximab vedotin (Bv),
vinblastine, dacarbazine and rituximab, with reduced dose anthracycline, in CAYA with
newly diagnosed intermediate and high risk cHL.
Lead OrganizationNew York Medical College
Principal InvestigatorMitchell S. Cairo
